Topic: Pay for delay

Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.

07 July 2022

Featured in US Courts Annual Review - Edition 3

In 2021, the United States Court of Appeals for the Second Circuit made key antitrust decisions in appeals from the United States District Court for the Southern District of New York.

24 June 2022

The UK’s antitrust watchdog has fined four pharmaceutical companies and a private equity group more than £35 million for agreeing to limit the supply of an anti-nausea tablet to the National Health Service, causing prices to rise by 700%.

03 February 2022

The Federal Trade Commission has withdrawn its case against AbbVie after a Supreme Court ruling in April determined that the agency does not have the authority to seek restitution or disgorgement under Section 13(b) of the FTC Act.

02 August 2021

A federal Kansas judge has dismissed a pharmacy operator’s putative class action accusing Mylan and Pfizer of illegally monopolising the market for epinephrine auto-injectors used to treat severe allergic reactions.

28 July 2021

Takeda Pharmaceutical and Endo International are facing a lawsuit over an alleged scheme to block generic competition to Takeda’s branded anti-constipation drug Amitiza.

28 June 2021

Servier has kicked off its bid to convince a UK court that national health authorities should have encouraged doctors to prescribe cheaper generic drugs to mitigate their losses from its pay-for-delay settlements relating to a blood pressure medication.

17 June 2021

A senior official at Servier may have to give evidence via videolink at a preliminary issues trial next week due to coronavirus restrictions, as the drugmaker seeks to prove that national health authorities in the UK should have mitigated any losses resulting from its alleged anticompetitive conduct.

09 June 2021

The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.

10 May 2021

There is substantial evidence to support the Federal Trade Commission’s conclusion that a pay-for-delay settlement between Endo Pharmaceuticals and Impax Laboratories violated federal antitrust law, the US Court of Appeals for the Fifth Circuit has ruled.

14 April 2021